Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 10Urogenital Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Metastatic Castration-resistant Prostate Cancer 1

Interventions

Nivolumab 2Ipilimumab 2vedolizumab 1gallium 68 PSMA-11 1fludarabine 1cabozantinib 1aldesleukin 1abiraterone 1abemaciclib 1Therapeutics 1Specimen Handling 1Prednisone 1Prednisolone 1Magnetic Resonance Spectroscopy 1LDP-02 1Interleukin-2 1Infliximab 1Immunoglobulin G 1Geriatric Assessment 1Fulvestrant 1Exercise 1Disulfides 1Cyclophosphamide 1CTLA-4 Antigen 1CT-P13 1Biopsy 1Androgen Antagonists 1Adrenal Cortex Hormones 1(225)Ac-PSMA-617 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Urogenital Neoplasms × abiraterone × Clear all
NCT05288166 2025-06-27

CYCLONE 3

Eli Lilly and Company

Phase 3 Active not recruiting
925 enrolled 12 charts
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms, Urogenital Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡